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Abstract
Background: PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for
whom a typical doctor might consider the prescription of statin therapy to be a realistic option.
Methods: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind,
placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of
coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women
with pre-existing vascular disease or with significant risk of developing this condition.
Results: In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and
3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0–9.0 mmol/l, were randomised.
Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared
to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular
disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women).
Conclusions: Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is
significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of
recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first
half of 2002 with the main results being available in the fourth quarter of 2002.
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Introduction
Previous trials of HMG Co-A reductase inhibitors [1–5]
have focused primarily on subjects under the age of 70
years. The PROspective Study of Pravastatin in the Elderly
at Risk (PROSPER) is a randomised, double blind, place-
bo-controlled trial to test the hypothesis that treatment
with pravastatin will diminish the risk of subsequent ma-
jor vascular events in a cohort of high-risk elderly individ-
uals with a wide range of cholesterol levels. The primary
endpoint is the composite outcome of coronary heart dis-
ease death, non-fatal myocardial infarction, and fatal or
non-fatal stroke. This report describes the outcome of
study recruitment, the baseline characteristics of the ran-
domised subjects, and contrasts the randomised subjects
with the total population of screenees.
Methods
Overview of study design and data acquisition
The study has been described in detail elsewhere [6]. Brief-
ly, PROSPER is designed to examine the benefits of prav-
astatin (40 mg per day) versus placebo in 70–82 year old
men and women with either pre-existing vascular disease
or elevated risk of such disease due to smoking, hyperten-
sion, or diabetes. Age-eligible individuals in the primary
care setting were invited to attend an initial screening visit
(S1) conducted by a study nurse, at which consent for the
screening process, a brief medical history, and vital signs
were recorded, and dietary and appropriate health advice
given. Data recorded included standard risk factors such
as age, sex, blood pressure, heart rate, body mass index,
history of hypertension, diabetes, smoking, and vascular
disease. At subsequent visits prior to randomisation, these
data were recorded again, along with alcohol consump-
tion (measured in units/week, with one unit being equiv-
alent to one glass of wine, one half pint of beer or one
standard measure of spirits), current medication use, and
details of previous major illnesses and ongoing chronic
conditions. In Scotland and Ireland, the subjects were in-
vited in an unselected manner. In the Netherlands, how-
ever, subjects were pre-selected on the basis of possession
of previously known cardiovascular risk factors. Subjects
who continued to be eligible after screening were invited
to a second screening visit (S2), at which a more detailed
medical history was taken and a fasting venous blood
sample drawn for biochemical and hematological checks
and lipoprotein quantification. If, on the basis of their
blood results, subjects were still eligible (plasma total
cholesterol 4.0–9.0 mmol/l [155–350 mg/dl], triglycer-
ides ≤  6.0 mmol/l [530 mg/dl]), they were invited to at-
tend a third screening (or first enrollment) visit (A1),
where another blood sample was taken, and the Mini-
Mental State Examination [MMSE] and various psycho-
metric tests (Picture-Word Learning Test, Stroop Word
Colour Test, Letter Digit Coding Test) were administered.
Subject to satisfactory placebo run-in compliance (≥  75%
but less than 120%), ECG reading, and MMSE score > 24,
subjects then attended a fourth screening (second enroll-
ment) visit (A2), at which time the psychometric tests
were re-administered as well as "activities of daily living"
questionnaires (modified Barthel and Instrumental Activ-
ities of Daily Living). Consenting and still-eligible sub-
jects were then randomised to study treatment. All
patients were expected to be sufficiently mobile to attend
the study randomisation visit at their general practition-
er's office. Further details of the inclusion and exclusion
characteristics are given in the study design paper [6]. The
target sample size was 5,500 subjects (3,000 women and
2,500 men) split approximately evenly between those
with and without a history of vascular disease.
All data were processed at the study data centre in The
Robertson Centre for Biostatistics, University of Glasgow,
Scotland. The fasting blood samples taken at visits S2 and
A1 provided full lipoprotein profiles obtained in the Cen-
tre for Disease Control – certified central lipoprotein lab-
oratory in Glasgow Royal Infirmary, Glasgow, Scotland.
At visit A1, a 12-lead ECG was recorded and automatically
Minnesota coded after electronic transmission to the cen-
tral ECG laboratory in the University of Glasgow Depart-
ment of Medical Cardiology at the Royal Infirmary,
Glasgow, Scotland [7].
Statistical Methods
Most of the analyses presented here are descriptive in na-
ture. Continuous variables are summarised as mean ± SD.
Data for categorical variables are presented as counts and
percentages of the total group of randomised or screened
subjects or subgroups as appropriate. Summary statistics
for plasma triglycerides are presented untransformed.
Table 1: Screening and randomisation experience in Scotland, 
Ireland and the Netherlands and in total. The table shows the 
numbers attending each visit and those randomised and these 
numbers as a percentage of those attending the initial screening 
visit (S1) within each country.
Scotland Ireland Nether-
lands
Total
Visit S1 11770 10157 1843 23770
Visit S2 4324 (37%) 4090 (40%) 1373 (74%) 9787 (42%)
Visit A1 3183 (27%) 3021 (30%) 1249 (68%) 7453 (31%)
Visit A2 2689 (23%) 2358 (23%) 1114 (60%) 6161 (26%)
Randomised 2520 (21%) 2184 (22%) 1100 (60%) 5804 (24%)Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/8
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Results
Recruitment
A summary of recruitment data is given in Table 1. In Scot-
land and Ireland, subjects were invited for screening with-
out pre-selection, with 11,770 and 10,157 subjects
attending for screening from each country, respectively.
Of these, similar percentages attended visits S2, A1, and
A2, and were eventually randomised (2,520 from Scot-
land and 2,184 from Ireland). In the Netherlands, only
1,843 subjects were screened, but due to the pre-screen-
ing, a much higher percentage was randomised, yielding
1,100 randomised subjects. Randomisation was complet-
ed between February, 1998 and May, 1999.
Comparison of Randomised subjects with the population 
of screenees
The 23,770 screenees are compared with the 5,804 ran-
domised subjects in Table 2. Summary statistics are pre-
sented for each country and for men and women.
Although there are some minor variations, the mean ages,
blood pressures, heart rates, and body mass indices do not
differ substantially across countries, genders, and between
the screenees and randomised subject groups. Subjects
were randomised on the basis of having a history of vas-
cular disease, defined by physician-diagnosed stable angi-
na or intermittent claudication, stroke, transient
ischaemic attack, myocardial infarction, arterial surgery,
or amputation for vascular disease (secondary prevention
cohort), or having a history of hypertension, diabetes, or
smoking in the absence of a history of vascular disease
(primary prevention cohort). Hence, not surprisingly,
these risk factors were more prevalent among the ran-
domised subjects. A history of vascular disease was more
common in men, a history of hypertension more com-
mon in women, and a history of diabetes more common
in subjects randomised in the Netherlands. These differ-
ences are driven by study entry criteria and by differences
in recruitment strategies as much as by differences in the
underlying populations.
Characteristics of the randomised subjects
Key risk factors and baseline medications for randomised
subjects are summarised in Table 3. The average age
ranged from 74.7–76.2 years among men and women in
the primary and secondary prevention groups. Three
thousand of the 5,804 randomised subjects were women
and 3,239 were in the primary prevention cohort. In this
elderly group of subjects, the systolic blood pressures were
higher than has been seen in previous prevention trials,
with average systolic blood pressures in the four sub-
groups ranging from 151.5–157.7 mmHg. In the primary
prevention cohort, 45% of men and 25% of women were
current smokers. The corresponding numbers were 21%
and 15% in the secondary prevention group. Consump-
Table 2: Comparison of all screenees (n = 23770) with randomised subjects (n = 5804) on the basis of data recorded at the initial screen-
ing visit (S1). Data are presented for Scotland, Ireland and for The Netherlands, and for men and women. Data are presented as mean 
(SD) for continuous variables and as % of column total for categorical variables.
Scotland Ireland Netherlands
Men Women Men Women Men Women
All 
Screenees
Randomised 
Subjects
All 
Screenees
Randomised 
Subjects
All 
Screenees
Randomised 
Subjects
All 
Screenees
Randomised 
Subjects
All 
Screenees
Randomised 
Subjects
All 
Screenees
Randomised 
Subjects
Number of 
subjects
5117 1237 6653 1283 4528 988 5629 1196 972 581 871 519
Continuous 
variables
Age (years) 74.9 (3.4) 74.7 (3.2) 75.4 (3.5) 75.4 (3.5) 75.3 (3.4) 74.9 (3.3) 75.7 (3.4) 75.4 (3.3) 74.7 (3.3) 74.5 (3.3) 75.3 (3.3) 75.3 (3.3)
SBP(mmHg) 156 (24) 158 (23) 154 (23) 155 (23) 158 (24) 160 (24) 155 (24) 158 (23) 160 (23) 162 (23) 159 (23) 160 (23)
DBP(mmHg) 85 (12) 84 (12) 84 (12) 84 (12) 85 (12) 85 (13) 84 (12) 85 (11) 87 (12) 88 (11) 87 (11) 87 (11)
Heart Rate 
(b.p.m.)
72 (13) 70 (13) 75 (12) 73 (13) 73 (13) 71 (13) 76 (12) 74 (12) 73 (13) 72 (12) 76 (12) 75 (12)
BMI (kg/m2) 26.2 (3.7) 26.4 (3.7) 26.2 (4.6) 27.0 (4.7) 26.6 (4.0) 26.8 (3.8) 26.2 (4.7) 27.0 (4.8) 25.8 (3.1) 26.0 (3.1) 26.7 (4.1) 27.2 (4.2)
Categorical
variables
Smoker:
Current 21.3 32.5 16.2 24.4 22.4 34.5 14.5 20.4 27.1 31.7 14.5 16.0
Former 54.9 48.4 32.6 32.3 52.7 45.5 27.6 24.8 65.4 61.3 30.0 27.2
Never 23.8 19.1 51.2 43.3 24.8 20.0 57.9 54.8 7.5 7.0 55.6 56.8
Diabetic 7.2 9.5 4.6 5.7 8.0 12.3 5.6 8.2 13.5 13.4 14.9 15.6
Hypertensive 28 47 35 64 32 49 44 74 44 51 61 74
Vascular
disease
38 56 28 42 32 47 23 31 48 53 30 34Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/8
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tion of alcohol was more frequent in males, with approx-
imately 12% of males consuming more than 20 units of
alcohol per week. Fifty-nine percent of men and 80% of
women had a history of hypertension in the primary pre-
vention cohort, and the prevalence of diabetes ranged
from 6.9%-14.7% across the four subgroups. In the sec-
ondary prevention group, the most prevalent indication
of vascular disease was a diagnosis of stable angina, with
approximately 60% having this condition. The next most
common vascular conditions were a history of myocardial
infarction and a history of transient ischaemic attack and
stroke. The use of beta blockers, calcium channel blockers,
ACE inhibitors, diuretics and nitrates reflects the high per-
centages of subjects who had a history of hypertension
Table 3: Risk factor distributions as measured prior to randomisation for men, women, high risk subjects with no history of vascular 
disease (Primary Prevention) and subjects with a history of vascular disease (Secondary Prevention). Data shown are mean (SD) for 
continuous variables and % of randomised subjects within each column for categorical variables.
Men Women
Primary Secondary Primary Secondary
Subjects (%) 1345 (23.2) 1459 (25.1) 1894 (32.6) 1106 (19.1)
Continuous variables
Age (years) 74.7 (3.2) 75.3 (3.3) 75.3 (3.3) 76.2 (3.4)
SBP (mmHg) 157.7 (21.7) 152.8 (22.2) 155.8 (21.3) 151.5 (21.8)
DBP (mmHg) 85.9 (11.4) 81.9 (11.4) 84.7 (11.2) 82.1 (11.5)
Height (cm) 172.5 (6.8) 171.7 (6.6) 159.1 (6.7) 158.4 (6.6)
Weight (kg) 79.1 (12.3) 78.4 (11.6) 68.9 (12.9) 67.4 (12.1)
BMI (kg/m2) 26.6 (3.8) 26.6 (3.4) 27.2 (4.7) 26.9 (4.6)
Categorical variables
Smoking: 
Current 45.1 21.0 25.1 15.2
Former 39.3 60.9 24.9 35.2
Never 15.6 18.0 50.0 49.6
Alcohol: 
0 units/week 25.8 32.6 58.6 58.2
1–13 units/week 47.9 43.6 36.5 38.3
14–20 units/week 12.7 12.8 3.6 2.3
> 20 units/week 13.6 11.0 1.3 1.3
History of:
Diabetes 14.7 10.4 10.5 6.9
Hypertension 59.3 43.4 80.3 57.9
Angina 0 59.1 0 63.1
Claudication 0 16.0 0 14.2
MI 0 36.9 0 21.5
Stroke 0 9.4 0 9.0
TIA 0 16.8 0 18.1
CABG 0 9.1 0 2.1
PTCA 0 4.7 0 2.7
PAD surgery 0 5.9 0 3.4
Medications
Beta Blockers 19.6 28.8 26.6 28.6
ACE-Inhibitors 15.4 15.9 17.4 16.5
A-II receptor antagonists 1.6 1.2 2.9 2.0
Diuretics 32.3 28.1 53.3 45.7
Calcium channel blockers 18.4 34.3 17.6 34.0
Nitrates 0 41.7 0 43.6
Aspirin/antiplatelets 14.4 68.1 15.2 56.9
Anti-coagulants 0.7 4.9 0.3 2.4
Other antihypertensives 4.9 4.5 4.5 1.8
Other anti-arrhythmic 1.9 3.8 1.7 3.9
Other anti-anginals 0 1.3 0 1.8
Blood glucose lowering:
insulin 1.2 0.5 1.1 0.7
oral hypoglycaemics 7.4 6.7 6.5 3.4Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/8
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and angina. Approximately 15% of subjects in primary
prevention were taking aspirin or other antiplatelet treat-
ment, as were 68% of men and 57% of women in second-
ary prevention.
The Minnesota Codes from the baseline ECGs were uti-
lised to classify ECGs into more descriptive terms such as
myocardial infarction, left ventricular hypertrophy, and
myocardial ischaemia. Table 4 shows the mapping that
was used for this purpose.
The average lipid profiles of the four main subgroups are
given in Table 5. As would be expected in an older popu-
lation, women have higher total cholesterol, LDL choles-
terol, and HDL cholesterol levels than men. However,
there are not substantial differences between the subject
groups included on the basis of primary or secondary pre-
vention.
An important contribution of the PROSPER study will re-
late to evaluation of the effect of pravastatin on cognitive
decline, activities of daily living, and use of health care re-
sources. Table 6 provides an assessment of cognitive func-
tion, activities of daily living, and resource utilisation.
Data are given for the MMSE and the Barthel and IADL
questionnaires, on living status, use of care facilities
(home help, meals on wheels, and district nurses), on re-
cent use of general practitioner, outpatient, and day hos-
pital services. There are no important differences in any of
these measures between the subjects recruited on the basis
of primary or secondary prevention. This may, in part, be
explained by the fact that all subjects were required to
have an MMSE score > 24 at baseline. The only obvious
gender difference is that men (25 %) are significantly less
likely to be living at home on their own than women
(54%).
Discussion
In the five previously published major trials of statins,
namely the Simvastatin Scandinavian Survival Study (4S),
the West of Scotland Coronary Prevention Study (WO-
SCOPS), the Coronary And Recurrent Events study
(CARE), the Long-term Intervention with Pravastatin in
Ischaemic Disease study (LIPID), and the Air Force/Texas
Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-
CAPS) [1–5], the average ages at baseline were 58, 55, 59,
62, and 58 years, respectively. Furthermore, in these stud-
ies only 19%, 0%, 14%, 17%, and 15%, respectively, were
women. PROSPER recruited a completely different popu-
lation, for which data on the clinical efficacy of statin
Table 4: Baseline ECG characteristics. Data shown are % of randomised subjects within each column.
Description Minneosta Codes Men Women
Primary Secondary Primary Secondary
Subjects(%) 1345 (23.2) 1459 (25.1) 1894 (32.6) 1106 (19.1)
Myocardial infarction – Definite 1–1 4.2 14.2 2.8 6.3
Myocardial infarction – Probable 1–2 (except 1-2-8) 4.0 9.6 3.6 4.8
Myocardial infarction – Possible 1–3 7.4 9.8 7.7 7.5
Left ventricular hypertrophy – Definite 3-1 and at least one of (4-1, 4-2, 5-1, 5-2) 3.2 3.4 3.1 6.1
Left ventricular hypertrophy – Possible 3-1 and (4-3 and/or 5-3) or 3-3 and at least 
one of (4-1,4-2,4-3,5-1,5-2, 5-3)
2 . 63 . 15 . 14 . 7
Myocardial ischaemia – Probable (4-1 and/or 4-2) and at least one of (5-1,5-2 
or 5-3)
1 . 82 . 93 . 14 . 3
Myocardial ischaemia – Possible 5-1 or 5-2 1.9 2.4 2.1 4.5
Non-specific T-wave changes 5-3 7.9 7.3 10.2 13.1
RVH Possible 3-2 0.1 0 0.2 0.1
Left axis deviation 2-1 10.6 9.0 8.0 8.1
Right axis deviation 2-2 or 2-3 0.5 0.6 0.3 0.3
Left bundle branch block 7-1-1 1.4 2.6 2.2 3.0
Right bundle branch block 7-2-1 or 7-8 7.0 6.5 2.4 2.3
Intraventricular conduction disturbances 7-4 2.8 7.6 1.6 3.3
Notes : the characteristics are coded according to the following hierarchies: (i) In the myocardial infarction categories, a subject is included only once in the cat-
egory corresponding to the most significant code, with definite having precedence over probable and probable precedence over possible. (ii) In the left ventricular 
hypertrophy categories, a subject is included only once in the category corresponding to the most significant code, with definite having precedence over possible. 
(iii)Subjects with a code corresponding to a definite, probable or possible myocardial infarction or a definite or possible left ventricular hypertrophy are excluded 
from the categories corresponding to probable or possible myocardial ischaemia or non-specific T-wave change. (iv) In the categories for myocardial ischaemia 
and non-specific T-wave changes, a subject is included only once in the category corresponding to the most significant code, with probable myocardial ischaemia 
having precedence over possible myocardial ischaemia which in turn has precedence over non-specific T-wave change.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/8
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Table 5: Baseline total, LDL, HDL and VLDL cholesterol and triglycerides for randomised subjects. Data are mean (SD). All units are 
mmol/l.
Men Women
Primary Secondary Primary Secondary
Subjects(%) 1345 (23.2) 1459 (25.1) 1894 (32.6) 1106 (19.1)
Total Cholesterol 5.30 (0.79) 5.39 (0.79) 5.97 (0.89) 6.03 (0.91)
LDL Cholesterol 3.52 (0.72) 3.63 (0.72) 3.96 (0.82) 4.05 (0.81)
HDL Cholesterol 1.22 (0.33) 1.14 (0.30) 1.38 (0.36) 1.35 (0.34)
VLDL Cholesterol 0.57 (0.33) 0.62 (0.38) 0.62 (0.35) 0.63 (0.38)
Triglyceride 1.43 (0.69) 1.55 (0.76) 1.58 (0.66) 1.61 (0.70)
Table 6: Baseline living status, use of care facilities, and GP, out-patient and day-hospital visits and assessment of activities of daily living 
scores (Barthel and IADL).
Variable Men Women
Primary Secondary Primary Secondary
Subjects [N(%)] 1345 (23.2) 1459 (25.1) 1894 (32.6) 1106 (19.1)
Assessments of activities of daily living [mean(SD)]
Barthel 19.9 (0.5) 19.8 (0.7) 19.7 (0.8) 19.6 (1.0)
IADL 13.7 (0.8) 13.6 (1.1) 13.7 (0.9) 13.4 (1.2)
MMSE (Visit A1) [mean(SD)]
Score 28.1 (1.5) 28.0 (1.5) 28.0 (1.6) 28.0 (1.5)
Living status [% of column total]
Home alone 25.6 23.6 53.8 55.2
Home not alone 73.2 74.4 43.6 41.0
Not home 1.2 2.1 2.6 3.9
Use of care facilities [% of column total]
Home help (days/week) 0 days 93.5 91.8 91.4 86.4
1 day 5.2 5.6 6.6 9.2
>1 day 1.3 2.7 2.0 4.3
Meals on wheels (days/week) 0 days 98.4 98.5 98.4 98.6
≥  1 days 1.6 1.5 1.6 1.5
District Nurse (days/month) 0 days 99.4 99.6 99.3 98.4
≥  1 days 0.6 0.4 0.7 1.6
GP and hospital visits previous 3 months [% of column total]
GP Surgery visits 0 39.4 36.5 33.8 33.5
1 29.7 32.0 32.0 27.2
>1 30.7 31.5 34.2 39.2
GP Home visits 0 97.7 96.2 96.0 93.6
1 1.6 2.9 2.6 4.2
>1 0.7 0.9 1.4 2.2
Outpatient hospital 0 83.1 79.4 84.3 77.6
1 13.5 15.2 12.4 18.2
>1 3.4 5.4 3.3 4.3
Day hospital 0 98.7 98.9 98.6 98.0
1 1.1 1.0 1.3 1.7
>1 0.2 0.1 0.1 0.3Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/8
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treatment are scarce. The PROSPER population is charac-
terised by an average age of 75 years and includes 52%
women. Subjects in both primary and secondary preven-
tion were recruited across a wide spectrum of baseline
cholesterol levels, thus providing a wealth of new infor-
mation on the benefits of statin treatment in a group of
elderly subjects with a very high risk of coronary and cer-
ebrovascular events. This population reflects the older pa-
tients in general practice, for whom statin treatment might
be considered. As the elderly are taking a wide range of
prescription medications, with many taking multiple con-
comitant treatments, PROSPER will provide an opportu-
nity for a rigorous assessment of the safety of pravastatin
treatment.
It is well known that the prevalence of ECG abnormalities
increases with age (Ashley et al [8]), a factor that should
be considered when examining the prevalence of baseline
ECG abnormalities in PROSPER. Furberg et al. [9] report-
ed on major ECG abnormalities in a random sample of
5,150 individuals aged 65 years and older. Although
numbers were small in those over 80 years, the prevalence
of any major ECG abnormality (myocardial infarction,
LVH, isolated ST-T changes, ventricular conduction defect,
atrial fibrillation, and first degree AV block) rose from
37.9% in men aged 65 to 69 years with coronary artery
disease and hypertension to 61.1% in men over 85 years.
Corresponding figures for women were 25.8% to 38.8%.
It is against this background that the approximate 25%
prevalence of myocardial infarction, LVH, and myocardial
ischaemia in both genders of the primary prevention
group forin this study needs to be considered. A small
number of individuals (2.0%) had both myocardial inf-
arction and left ventricular hypertrophy. In every major
category, as expected, the prevalence of abnormalities in
the secondary prevention group was higher than in the
primary prevention group, while the prevalence of LVH in
women was higher than in men, as noted by Furberg et al.
[9]. The reverse was true for myocardial infarction. In the
PROSPER sample, a history of myocardial infarction in
36.9% of males and 21.5% of females closely parallels the
ECG findings of infarction in 33.6% of males and 18.6%
of females in the secondary prevention group.
A particularly novel aspect of the study is the collection of
detailed longitudinal data on various elements of cogni-
tive function, activities of daily living, and health care re-
source utilisation. These data will add significantly to the
information collected on clinical events by providing a
detailed profile of the PROSPER recruits, with regard to
important aspects of quality of life in the elderly, and the
cost-effectiveness of treatment with pravastatin. A more
detailed analysis of the baseline cognitive status of study
subjects, and a design paper for the proposed economic
analysis will be published elsewhere. Recently [10], the
WOSCOPS investigators published findings suggesting a
link between treatment with pravastatin and prevention
of diabetes. PROSPER will provide an opportunity to con-
firm this finding. The study has achieved its first goal of re-
cruiting more than 5,500 high-risk men and women, over
the age of 70 years. Follow-up is ongoing, and the study
should complete all subject visits in the first half of 2002.
The main results will be available in the fourth quarter of
2002.
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